Recently, endpoints for clinical trials have been changing from measuring clinical response to mucosal healing in ulcerative colitis. Endoscopic evaluation is the current gold standard to assess mucosal lesions and has become a major measure of therapeutic efficacy in addition to patients reported outcomes.
SUMMARY Background
Recently, endpoints for clinical trials have been changing from measuring clinical response to mucosal healing in ulcerative colitis. Endoscopic evaluation is the current gold standard to assess mucosal lesions and has become a major measure of therapeutic efficacy in addition to patients reported outcomes.
Aim
To achieve consensus on endoscopic definitions of remission and response for clinical trials in patients with ulcerative colitis.
Methods

In reaching the current international recommendations on an International
Organization For the Study of Inflammatory Bowel Disease (IOIBD) initiative, we first performed a systematic review of technical aspects of endoscopic scoring systems. Then, to achieve consensus on endoscopic definitions of remission and response for clinical trials, we conducted a two-round vote using a Delphi-style process among fifteen specialists in the field of inflammatory bowel diseases.
INTRODUCTION
Accumulating evidence indicates that mucosal healing is associated with better outcomes during the course of ulcerative colitis (UC) including decreased need for colectomy, reduced rates of hospitalisation and increased rate of steroid-free remission. 1 The absence of endoscopic healing is associated with an increased risk of dysplasia and colorectal cancer. 1 As recent advances in the medical therapy of inflammatory bowel diseases (IBD) have made mucosal healing a realistic goal, endoscopic indices are increasingly used both in clinical trials and practice. Many scoring systems have been developed in UC to evaluate endoscopic disease activity, but none has yet had all properties fully assessed. As a consequence, most studies addressing mucosal healing have used arbitrary definitions for endoscopic response or remission. Required qualities of any instrument are the following:
(i) reproducibility (does the instrument produce the same or similar results in individuals on different occasions or by different observers?)
(ii) validity (does the instrument measure what is intended?) (iii) responsiveness or sensitivity-to-change (is the instrument able to measure change in an individual when it does occur?)
We achieved an international consensus on definitions of endoscopic response and remission in UC through a two-step process. The purpose of this paper on the International Organization For the Study of Inflammatory Bowel Disease (IOIBD) initiative was first to review technical aspects of scoring systems for UC (available indices, definitions, construction, strengths and weaknesses), and then to develop a consensus definition among experts in the field of IBD regarding endoscopic response and remission in UC, using a Delphi-style process.
AVAILABLE ENDOSCOPIC SCORING SYSTEMS FOR UC
First scores
The first description of endoscopic features in UC was reported by Truelove and Witts in 1955 (Table 1) . 2 In this landmark randomised controlled trial of hydrocortisone therapy, sigmoidoscopic findings were classified at the end of the treatment course as normal or near normal (slight hyperaemia or slight granularity), improved, unchanged or worse, based on the physician's global evaluation. A pioneer work was performed introducing the Baron score in 1964, 3 followed by a host of other scores, Sutherland et al., 4 Feagan et al., 5 Matts et al., 6 Blackstone et al., 7 Rachmilewitz et al. 8 Descriptions and
properties of these scores are presented in details in Data S1. None of these scores have been validated.
The Mayo Clinic score and its endoscopic sub-score Definition. Schroeder et al. 9 performed serial flexible proctosigmoidoscopic assessments during a placebo-controlled trial of oral delayed-release mesalazine (mesalamine). 9 They defined a priori an endoscopic subscore ranging from 0 to 3 with the following characteristics for grading:
(i) normal or inactive disease (0); (ii) mild disease (erythema, decreased vascular pattern, mild friability) (1);
(iii) moderate disease (marked erythema, absent vascular pattern, friability, erosions) (2); (iv) severe disease (spontaneous bleeding, ulcers) (3).
9
The descriptors were not precisely defined and, like the original Baron score, there was overlap between descriptors used for different grades. To improve clarity, several randomised controlled trials [10] [11] [12] have used a modification to exclude any friability from grade (1). Friability has subsequently been defined as the presence of bleeding following gentle contact with the endoscope during insertion.
13
Strengths and weaknesses. The Mayo score has been the most commonly used in clinical trials until now (2016), but it has not been validated. It does, however, show good reproducibility between experienced observers. 13, 14 In the same study 13 that evaluated performance characteristics of the modified Baron score among 7 IBD specialists reading 50 videosigmoidoscopies, the intraclass correlation coefficient was 0.79, known to be equivalent to a weighted kappa statistic using square distance weights, a tool that overestimates agreement by giving much too important contribution of large disagreements to agreement, when compared to standard unweighted Kappa. 15 In another study, 16 good concordance for the Mayo Clinic endoscopy sub-score was shown between experienced endoscopists, but not among trainee endoscopists. However, there was a major methodological pitfall, since the kappa value between the ratings of experienced and trainee endoscopists used a gold standard defined as the mean of the evaluations of experienced endoscopists. severe UC. The score has 6 descriptors, each with a level increasing from 0 to 2 or 3 according to severity: ulcer size (3), ulcer depth (3), redness (2), bleeding (3), mucosal oedema (3), mucus exudate (2). The value given to each of these lesions was decided arbitrarily and not derived from statistical analysis. Pictures of typical endoscopic appearances for each level are provided in the publication.
Strengths and weaknesses:
Results from applying the EAI in videosigmoidoscopies from 396 patients with UC were correlated with those obtained using the Matts, Rachmilewitz and Lichtiger scores of disease activity. The latter is solely a clinical activity index, although widely used in trials of severe UC. Notably, there was a fairly wide range of EAI scores for those patients with the highest Matts' or Rachmilewitz endoscopic score, suggesting that the EAI could provide a more precise grading of severe lesions. 18 Colonoscopies were repeated within 30 days in 25 patients to evaluate treatment efficacy. The relationship between changes in the clinical activity (Lichtiger) index and endoscopic scores was evaluated. The median EAI was shown to change significantly in those who achieved clinical remission (n = 8/ 25) and in those who responded to medical treatment (n = 10/25), but not in those who had no response (n = 7/25), while neither the Matt's nor Rachmilewitz scores were as sensitive to change. 18 The authors did not use standard tools to assess responsiveness and the very limited sample size render results open to question.
Ulcerative Colitis Colonoscopic Index of Severity (UCCIS). Definition: Thia et al. from the Mayo Clinic developed a full colonoscopy severity index, the UCCIS. 19, 20 Colonoscopy videos from 51 patients were assessed by 7 gastroenterologists, segment by segment (caecum/ascending, transverse, descending, sigmoid, rectum), for 10 a priori defined descriptors which were scored between 0 and 2, 3 or 4 for specific descriptors, as well as for segmental endoscopic severity (4-point scale) and global endoscopic severity (4-point scale and a 10-cm visual analogue scale). Inter-observer agreement for the 10 descriptors, segmental and global assessment of endoscopic severity was studied. The UCCIS was then derived from multivariate regression modelling of segmental assessment of endoscopic severity as a function of descriptor scores, with coefficients averaged across segments and then approximated for simplification. The UCCIS is calculated as the weighted sum over each segment of four descriptors (weighting in brackets): (i) granularity (3.6), (ii) vascular pattern (3.1), (iii) ulceration (3.5) and (iv) bleeding/friability (2.5).
19, 20
Strengths and weaknesses: In its final version, the UCCIS accounted for 85% of the variation between observers in their assessment of global endoscopic severity using the visual analogue scale (P < 0.001). 19 Interobserver agreement for scoring descriptors was assessed using Lin's concordance correlation coefficient, a tool with the same limitations as the intraclass correlation coefficient (above). The estimates of agreement were similar for granularity, vascular pattern and ulcers (between 0.55 and 0.77 across segments), but lower for bleeding/friability (between 0.34 and 0.66). In a second study on a different set of 50 patients, the authors confirmed the good inter-observer agreement for the descriptors involved in the UCCIS with the global assessment of endoscopic severity. 20 The concordance correlation coefficients varied between 0.70 and 0.85 across segments for granularity, vascular pattern and ulcers, but between 0.56 and 0.77 for bleeding/friability 20 (as was observed in the study developing the UCEIS 21 ). The UCCIS was validated on this new sample, accounting for 80% of the variation in the overall assessment of severity using the visual analogue scale. Sensitivity-to-change after a treatment with known efficacy has yet to be evaluated.
Ulcerative colitis Endoscopic Index of Severity. Definition: The UCEIS 21, 22 was developed from a two-phase study using a library of 670 videosigmoidoscopies from trials of mild-to-moderate active UC (total Mayo Clinic scores 0-11), augmented by 10 videos from five people without UC and five hospitalised patients with acute severe UC. 23 (see Data S2 for phase 1 and phase 2 UCEIS construction). As the original score had assigned '1' to normality for each descriptor, the original range of the UCEIS was 3-11, so the assignment of levels was rebased to zero without any other change in the descriptors (UCEIS score 0-8 22 ): (i) vascular pattern scored 0 to 2, (ii) bleeding scored 0 to 3, and (iii) erosions and ulcers scored 0 to 3.
Strengths and weaknesses:
The 57 videos aligned to a range on the 100 point visual analogue scale of 4-94, indicating that the videos appropriately captured the full range of endoscopic severity of UC. 22 There was a high level of correlation between UCEIS scores and overall assessment of severity on visual analogue scale (correlation coefficient, 0.93). The inter-investigator reliability ratio for overall assessment of severity was 0. The evaluation of the UCEIS has also been shown to be reproducible among seven IBD specialists reading 50 videosigmoidoscopies of patients with mild-to-moderate active UC (intraclass correlation coefficient of 0.83, with the limitations indicated above). 13 Using data from a randomised trial comparing mesalazine and placebo in mild-to-moderate active UC, central reading provided a consistently lower absolute treatment effect in the placebo group compared to local investigators, resulting in a greater treatment effect between the placebo and active treatment groups. 13 The responsiveness of the UCEIS was quantified using these videos, with a Guyatt's responsiveness measure and Cohen's effect size of 0.49 and 0.58 respectively. Although numerically higher than those observed for the modified Baron's score or modified Mayo endoscopic sub-score (above), responsiveness of the UCEIS remains to be fully defined. 17 A Japanese group has compared the responsiveness of the UCEIS with the Mayo endoscopic subscore in a retrospective study of 41 patients treated with tacrolimus. 25 The mean UCEIS improved from 6.2 AE 0.9 to 3.4 AE 2.1 (P < 0.001), but the pre-and post-treatment Mayo scores were not significantly different, probably because it could not discriminate on the size of ulcers, so a proportion of patients still scored 3 after treatment. 25 Segmental variation in UCEIS scoring has been examined, 26, 27 but the simplicity of the three-descriptor index applied to the most severely affected area at flexible sigmoidoscopy is appealing.
In conclusion, the new scores, especially the UCEIS, have been constructed using a much more rigorous methodology than earlier indices. This represents progress although the indices have not been validated in all dimensions and have not been fully evaluated in terms of sensitivity-to-change. What matters is that endoscopists use a common language when describing the endoscopic severity of UC, both in clinical trials and clinical practice.
Endoscopic remission and response in UC clinical trials The definitions of endoscopic remission and response in UC lacks consistency between clinical trials, 2, 12, takes no account of inter-observer variation in endoscopic scoring, and with rare exceptions have not been related to future outcome. It is hardly surprising that this has an impact on outcomes with regulatory implications. 13 This is illustrated by the comprehensive table of definitions for endoscopic remission and response in UC clinical trials provided in this review (Table 2) .
INTERNATIONAL CONSENSUS FOR ENDOSCOPIC DEFINITIONS OF REMISSION AND RESPONSE IN ULCERATIVE COLITIS CLINICAL TRIALS Methods
To establish a consensus for defining endoscopic remission and response in UC we performed a vote using a Delphi-style process. 68 The first step consisted of a literature review. A systematic search in databases (Pubmed, Medline, Embase) and international congress abstracts was performed, from which definitions of endoscopic outcome parameters for remission and response in UC trials were extracted ( Table 2 ). The eligibility criteria of studies were: studies published in English between 1955 and 2014; randomised controlled trials, clinical controlled trials, open label studies; studies with a population of 10 or more patients; studies with subjects 18 years of age and older; studies including patients with ulcerative colitis. A total of 15 specialists in the field of IBD, 11 of them among the IOIBD, from nine countries from Western Europe, North America and Australia participated in the process, which was conducted through an Internet survey. All of them were provided with the results of the systematic review. At each step of the process, participants were blinded to the votes of others. For the first round of the vote, each of the 15 specialists was asked to rate the importance of the selected outcome measurements for endoscopic remission and endoscopic response. After analysis of the results by the investigators, the four definitions with the highest median rank were selected and ordered by increasing median rank. In case of equal median rank, the definitions were ordered by increasing mean rank (Figure 1 ). In the second round of the vote, each Delphi panellist received a questionnaire that included these four definitions, with the first round's median rank and histogram of each definition summarised by the investigators. Specialists were again asked to rank-order the four definitions. Finally, for each definition, the proposition with the highest median rank was selected. In addition to median and mean rank, the proportion of specialists who ranked each definition first and first or second were given.
Second, to exclude the potential bias of UCEIS vs. Mayo endoscopic score specialists' personal preferences due to their geographic origins, we compared votes' results of European vs. North America experts.
RESULTS
After the specialist panel opinion, eight definitions were retained for endoscopic remission in UC, and five definitions were retained for endoscopic response in UC, for the vote (Table 3) . N.D. 6 weeks RCT UCDAI, Ulcerative Colitis Disease Activity Index (also called Sutherland index); mMayo, modified Mayo and mUCDAI, modified UCDAI, mucosal friability was given a score of 2 rather than 1; OL, Open Label; MMX, multi-matrix system; RCT, randomised controlled trial. For the eight proposed definitions of endoscopic remission in UC (Table 3) , the four definitions with the highest rank on the first round of the vote, by increasing mean rank, were ( Figure 1 ): (i) UCEIS 0; (ii) Mayo endoscopic sub-score 0; (iii) UCEIS≤1; (d) Mayo endoscopic sub-score ≤1. After the second round of the Delphi-style process, UCEIS 0 ranked first, with the highest median rank (median 1, mean 1.6).
Regarding the five definitions of endoscopic response in UC (Table 3) , the four definitions with the highest rank after the first vote, by increasing mean rank, were: (i) decrease in Mayo endoscopic sub-score ≥1 grade; (ii) decrease in UCEIS ≥2 points; (iii) decrease in UCEIS ≥2 point or UCEIS = 0; (iv) decrease in UCEIS ≥1 point. After the second round of the global voting, two definitions were ranked ex aequo with equal median rank of 2, almost equal mean rank, and a high proportion of investigators ranking them 1 or 2 (respectively 0.87 and 0.60): decrease in UCEIS ≥2 points (median 2, mean 1.93) and decrease in Mayo endoscopic sub-score ≥1 grade (median 2, mean 2.07).
In the European vs. North America comparison, the selection at the first round of the vote, and the two-first ranks at the second round were the same among European and American endoscopists (see Data S3).
DISCUSSION
For remission and response in UC, numerous scores and indices have been proposed over the past thirty years. The Mayo Clinic endoscopic sub-score, first published in 1987, 9 is still the one most used in clinical trials, as well as in endoscopic rooms worldwide. To decrease the very wide variation in endoscopic interpretation of UC disease severity between specialists, the UCEIS has recently been elaborated and further validated. 21, 22 These two scores were ranked first and/or second by the IOIBD group for endoscopic definitions of remission and response, with a preference for the UCEIS 0 for endoscopic remission, albeit that there are only preliminary data on specific reproducibility of UCEIS 0, and needs further assessment. The UCEIS is currently the most validated tool for assessing the endoscopic severity of UC. Nevertheless, further studies are required to establish thresholds, the clinical relevance of different UCEIS scores, and to explore more deeply its sensitivity-tochange. The four last definitions of endoscopic remission and the last one of endoscopic response were not part of the second vote due to their poor performance at the first vote according to the 15 specialists.
It should be acknowledged that when both the Mayo Clinic endoscopic sub-score and the UCEIS are performed by qualified blinded central readers, the kappa values are similar. 13 Training endoscopists on precise definitions and the scoring of the lesions, as well as calculating endoscopic indices are essential before using the scores in clinical trials. A training tool for the UCEIS is freely available on line (www.e-learning.ecco-ibd.eu). It should also be recognised that the role of central reading in randomised controlled trials for CD and UC is crucial; it has become clear that the choice of combined clinical and endoscopic outcome criteria leads to a reduction in placebo responses, 69 especially when central reading of the endoscopic records is performed. 13 It was notable that both UCEIS 0 and Mayo Clinic endoscopic sub-score 0 had higher median ranks in both rounds of voting, compared to UCEIS or Mayo Clinic endoscopic sub-score ≤1, although clinical trials to date have defined endoscopic mucosal healing as a (modified) Mayo Clinic endoscopic sub-score ≤1. That reflects the direction of travel in trial design to reduce the placebo rate of remission and to raise the expectations for patients. Patients with a Mayo endoscopic sub-score 1 have been shown to have a higher risk of relapse in the following year than those with Mayo endoscopic subscore 0, regardless of the extent of disease. In the post hoc analysis of infliximab trials, a Mayo endoscopic subscore of 0 discriminated from a score of 1 with regard to symptoms and steroid-dependency, although not colectomy: an endoscopic sub-score of 0 at week 8 predicted symptom relief (stool frequency or 1-2 more than normal each day, but no rectal bleeding) at weeks 30 and 54 in 71% and 74%, respectively, compared to 51% and 47% for a score of 1 at week 8. 70 Patients with an endoscopic sub-score of 0 at week 8 in the ACT 1 trial had a higher rate of steroid-free remission at week 54 (63%, 22/32) than those with a score of 1 (46%, 25/54). 46 In a prospective study of 187 patients with endoscopic remission (Mayo sub-score 0 or 1), 9% with Mayo sub-score 0 relapsed during the first 6 months of follow-up, compared to 37% with Mayo endoscopic sub-score 1 (P < 0.001). 71 Interestingly, preliminary work from Japan suggests that the UCEIS (0 vs. 1 or 2) may be able to discriminate outcomes over 2 years in those with a Mayo endoscopic sub-score 0. 72 Among 84 patients with a
Mayo Clinic endoscopy sub-score of 0, 19/20 (95%) of those with a UCEIS of 0 remained in remission for 23 months, compared to 48/64 (77%) with a UCEIS of 1 or 2. 72 Furthermore, in the referral centre UC cohort in Nancy, France, in 55 patients with a Mayo endoscopic sub-score of 0 or 1, 8/55 (15%) came to colectomy during a median follow-up of 48 months, all with a Mayo endoscopic sub-score of 1 at first evaluation. 73 Comparing survival curves, a Mayo endoscopic sub-score of 0 was associated with a lower rate colectomy than a subscore of 1 (P = 0.05). 73 A UCEIS score of 0 or Mayo endoscopic sub-score 0 seems the appropriate therapeutic target for patients with UC if one aims to change disease course, and histological healing may represent the ultimate therapeutic goal. 74 After reviewing technical aspects of available indices in UC through a Delphi-style process, international specialists have agreed on recommendations for endoscopic definitions of remission and response in clinical trials (evidence level 3, grade of recommendation C): Statement 1: definition of endoscopic remission is UCEIS 0. Statement 2: definition of endoscopic response is a decrease in Mayo endoscopic sub-score ≥1 grade or decrease in UCEIS ≥ 2 points.
These definitions and recommendations should be subject to prospective testing in clinical trials of UC. 
SUPPORTING INFORMATION
